Canaccord Genuity initiated coverage of GreenLight Biosciences with a rating of Buy and set a new price target of $4.00

Credit Suisse initiated coverage of GreenLight Biosciences with a rating of Outperform and set a new price target of $5.50

LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced the closing of its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent"), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the "Merger"). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the "NASDAQ") before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each r

LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of GRNA to a group of buyers led by Fall Line Capital, LLC for $0.30 per share in cash. If you are a GRNA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Arlington Asset Investment Corp. (NYSE:AAIC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connect

LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that the Company has entered into a definitive agreement (the "Merger Agreement") to be acquired by a group of buyers led by Fall Line Capital, LLC ("Fall Line") in an all-cash transaction valuing the Company at approximately $45.5 million. Pursuant to the terms of the Merger Agreement, and subject to the conditions set forth therein, Fall Line, together with its affiliates, agreed that it will commence a tender offer (the "Offer") to acquire all of the outstanding shares of common stock of the Company (the "Company Common Stock"), other t

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (NASDAQ:GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, today reported operational highlights and financial results for the first quarter ended March 31, 2023. "GreenLight is sharply focused on its mission, leveraging scientific expertise, global partnerships, and the power of our platform to progress innovative RNA-based products for plant health and human health," said Andrey Zarur, CEO of GreenLight. "Following regulatory submission of our Varroa mite honeybee solution in the first quarter, we now have two products under EPA review. Pending re

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (NASDAQ:GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest problems in human health and agriculture, today released its inaugural Sustainability Report. The report contains the company's sustainability roadmap and includes sustainability updates on its business areas—from developing new tools for farmers that are designed to be targeted, effective, and environmentally responsible to vaccine candidates and potential therapies to improve global health outcomes. The report highlights seven agriculture products that could reach the market by 2026, subject

BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (NASDAQ:GRNA) ("GreenLight" or the "Company"), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest problems in human health and agriculture, today, confirmed that it has received a non-binding indication of interest from Fall Line Endurance Fund, L.P. ("Fall Line") to acquire all of the outstanding capital stock of the Company for $0.60 per share in cash (the "Proposed Transaction"). The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of de

Two agriculture solutions now under regulatory review, pending EPA approval: Calantha™, a solution to protect potatoes, and a separate solution to protect honeybees from Varroa miteUpdated clinical strategy to accelerate development of its next-generation Covid vaccine candidate; decision to advance universal pan-sarbecovirus vaccine candidatePresented promising preclinical immune response data for Shingles vaccine candidate, first program in partnership with Serum Institute of India Private Limited BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (NASDAQ:GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's to

-- Progressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital efficient strategy targeting unmet medical needs, in both the developed and lower- and middle-income countries (LMICs), pairing focused R&D spend with partnerships -- Accelerating development of next-generation COVID vaccine candidate; decision to advance universal pan-sarbecovirus vaccine candidate in place of mono-valent Wuhan based antigen. -- Preclinical data on shingles vaccine candidate(s) showing high and durable antibody response, strong cellular T-cell response, and durable memory response -- Collaboration with EpiVax therapeutics t

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (NASDAQ:GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest problems in human health and agriculture, today announced it will host a two-part R&D Day Series for analysts and investors.  Session One: Plant Health Date: Tuesday, March 7th, 2023Time: 10:30 a.m. – 1:30 p.m. ETLocation: GreenLight Biosciences North Carolina Biotech Center in Research Triangle Park, NC Session Two: Human Health Date: Thursday, March 9th, 2023Time: 10:30 a.m. – 1:30 p.m. ETLocation: GreenLight Biosciences Headquarters in Lexington, MA The event will provide a

15-12G - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

8-K/A - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

EFFECT - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

EFFECT - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

POS AM - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

POS AM - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

S-8 POS - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

25-NSE - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

8-K - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

SC 13E3/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)